This trial is evaluating whether m-health cardiac rehabilitation will improve 1 primary outcome and 3 secondary outcomes in patients with Heart Failure. Measurement will happen over the course of 6 months.
This trial requires 20 total participants across 2 different treatment groups
This trial involves 2 different treatments. M-health Cardiac Rehabilitation is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
There is no single 'cure' for heart failure, and the only hope appears to be in the creation of a more 'perfect' form of life.
Heart failure is a group of disorders characterized by a low output of blood to the muscles and to the body’s organs. The most common heart failure is congestive heart failure. heart failure has different types of causation. This disease has a major influence on health and lives of people. heart failure is frequently an insidious disease. heart failure’s main causes are as a result of aging (coronary artery disease, valvular heart disease) and genetic disorders (inherited defects).
Atherosclerosis contributes to heart failure and vascular calcification accounts for a substantial proportion of heart failure. Patients with heart failure have low blood levels of vitamin D and high serum calcitriol levels.
Despite receiving the M-health CR intervention comparably to the placebo, improved clinical outcomes were documented. In addition, our findings suggest a benefit on cardiac functional capacity which was not found during the follow-up period. M-health CR, as a complementary intervention strategy, remains a promising one given that the burden of cardiometabolic disease, especially type 2 diabetes is rising.
The annual number of people with heart failure increased from 1.9 million in 1995 to 2.0 million in 2004 in the United States. This increase is driven by an increase in the number of people >65 years old and to a lesser extent, an increase in the number of people per year hospitalized with heart failure.
Signs of heart failure include dyspnea, heaviness of legs and abdomen, and, in advanced cases, reduced consciousness or confusion. Many signs also involve the cardiac function.
Most individuals with heart failure are not treated but rather managed medically. As a person progresses from being newly diagnosed, to having congestive heart failure, to a more advanced stage, there is growing evidence that more costly and aggressive management may produce better long-term outcomes at all stages of the disease. More randomized trials comparing different management approaches may answer the debate about optimal care.
Heart failure patients have many new treatments which may improve their condition; more is yet to be discovered. At present the available therapies are very limited and many with the condition are left with no prospects of cure. The development of new medicines is in its infancy although considerable effort is being made in the field. Nevertheless many possibilities for the development of treatment for heart failure have not yet been explored. In view of the huge number of patients affected by this condition and the growing demand for treatment to be available, there is a necessity to further expand our knowledge in this area. I have presented some new concepts and potential therapeutic targets that may hopefully prove to be useful for treating heart failure.
Serious heart failure can have a detrimental impact on a patient's ability to achieve their goals and expectations. It is important to identify those who have heart failure and use them to improve their lives so they can stay in their homes.
In a recent study, findings demonstrates that the use of smartphone technology for cardiac rehabilitation is acceptable to participants, and a potentially important tool for increasing participation in exercise.
Cardiovascular patients at highest risk for readmission are those with the most comorbidities and those requiring supplemental oxygen as their main therapies because of restrictive pulmonary function. These patients are at high risk of death. In a recent study, findings suggests that our M-health cardiac rehabilitation program achieves improved outcomes for patients with increased comorbidities who are more likely to be discharged to the home setting and are more likely to die.
The M-health cardiac rehabilitation program delivered to patients with cardiovascular disease resulted in measurable health benefits through reduced risk of cardiovascular mortality. The findings support the feasibility and superiority of providing CVD prevention services in the chronic care setting.